

# The role of donors in assuring quality of medicines: (how) can we harmonize the audits' practices


and the purchase policies?

DEVCO/B4, 20 Nov 2018, Brussels



## Access to quality medicines: DEVCO approach

- 2030 Agenda for Sustainable Development / EDC/aid effectiveness principles
- 2017 European Consensus on Development / 2010 Communication on the EU role in global health: comprehensive HSS



- Adherence to WHO standards: prequalification, MQAS
- QA delegated to GHIs (GFATM, GAVI, UNFPA supplies); reliance on procurement agents predominantly international ones- to adhere to best practices
- No distinct QA policy/guidelines for pharmaceutical products

(European Medicine Agency's assessments for markets outside EU, ECHO/QUAMED, EDCTP/R&D of medicines needed in LMICs)



### One dedicated multi-country program: The Renewed Partnership on strengthening pharmaceutical systems


- EU/ACP/WHO
- 2012-2017, 10 M EUR
- **Objective:** strengthen pharmaceutical systems and improve availability, affordability and use of quality essential medicines for priority communicable and NCDs in 15 African countries
- **5 results areas, including quality (35% of budget):** *`improved quality of medicines and reduced occurrence of falsified medicines and of medicines that do not meet safety standards, through the enforcement of medicines regulations and quality assurance systems'*
- ⇒ Support to National Medicines Regulatory Agencies (NMRAs)
- ✓ At country level: TA for strengthening NMRAs, developing tools & guidelines, strengthen pharmacovigilance systems; specific training for regulation/QA of bloodproducts
- ✓ *At REC level:* TA for medicines regulatory harmonisation

Burundi, Cameroun, Congo Brazza, Congo DRC, Ethiopia, Ghana, Guinea Conakry, Kenya, Mali, Mozambique, Senegal, Tanzania, Togo, Zambia, Zimbabwe



### In bilateral health programs: Strengthening national procurement and supply chain systems

#### **Example of DRC**:





## Challenges

- Stringent donor-driven quality requirements for ARVs, anti-TB and anti-malarial, but for a wide range of essential medicines: no internationally accepted certification process
- Many LMICs have either weak or absent regulatory systems

=> As QA is delegated to implementers & international procurement agencies due to weakness of regulatory framework, NMRAs are sidelined , which weakens national regulatory capacity further

- Same with procurement: reliance on international agents results in fragmented procurement channels in countries; national procurement entities often sidelined
- Multiplicity of standards and difficulty to apply them
- Lack of cooperation
- Affordability vs quality
- Globalisation of the market
- Growing issue of substandard medicines
- Quality control and QA: blurred concept for many actors



## **DEVCO's standpoint going forward**

Contribute to the development of a more conducive environment for access to quality essential medicines in low income countries. This requires:

- Addressing availability, affordability, acceptability & use, safety and quality
- Increasing cooperation, information sharing, common approaches (recommendations from 2011 WHO-GF Joint stakeholder meeting on QA of essential medicines)
- Harmonizing donor policies, standards, approaches to QA and assessment tools for essential medicines
- Strengthening NMRAs and country-based (national) procurement centres
- Supporting regional cooperation: in RECs + African Medicines Agency
- Important coordination and technical role of WHO

Pragmatic approach: optimize use of existing mechanisms while building country ownership and regulatory capacity





## Thank you